Jordanian drugmaker Hikma Pharmaceuticals HIK.L raised full-year revenue expectations for its injectables division, its largest unit, for the second time in three months as it supplies more opioid painkillers amid a shortage in the United States.

The company's shares rose 7.2 percent in early trading after it forecast injectables revenue of $825 million-$850 million, up from its previous estimate of $775 million-$825 million.

Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at top supplier Pfizer .

To take advantage of the shortfall, Hikma has been focusing on the manufacture of opioid products such as fentanyl, meperidine and morphine.

London-listed Hikma also raised full-year expectations for its generics division.

Generics revenue for the full-year is now expected in the range of $675 million to $700 million, the company said, up from $600 million to $650 million projected earlier by the company.

In a separate statement, Hikma said it signed an agreement with Vectura Group plc VEC.L for the global development and commercialisation of generic versions of GSK's GSK.L Ellipta portfolio.

(Reporting by Sangameswaran S in Bengaluru Editing by Saumyadeb Chakrabarty) ((Sangameswaran.S@thomsonreuters.com; within U.K +44 020 7542 1810; outside U.K. +91 80 6749 3544; Reuters Messaging: Sangameswaran.S.thomsonreuters.com@reuters.net))